MedTrace Logo

Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions

NCT00627536 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2008-03-04

No results posted yet for this study

Summary

This study was undertaken to investigate the scar-improvement efficacy and safety of a single dose of avotermin (Juvista) injection into skin incisions.

Conditions

  • Cicatrix

Interventions

DRUG

Avotermin

A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.

DRUG

Placebo

Matched to avotermin dosage strength

Sponsors & Collaborators

  • Renovo

    lead INDUSTRY

Principal Investigators

  • James Bush, MBChB · Renovo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627536 on ClinicalTrials.gov